A rapid point-of-care test to improve PrEP adherence
We are developing a novel point-of-care test to detect the presence of tenofovir—the most common drug in both ART and PrEP treatments worldwide—and we plan to establish the feasibility, acceptability, and validation of the rapid tenofovir test in a real-world PrEP clinic.
Active Dates
12/18/2017 to 11/30/2020
Faculty Involved